Throughout the last three months, 8 analysts have evaluated NovoCure (NASDAQ:NVCR), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for NovoCure, presenting an average target of $24.0, a high estimate of $42.00, and a low estimate of $15.00. Observing a downward trend, the current average is 1.19% lower than the prior average price target of $24.29.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of NovoCure's perception...
Login or create a forever free account to read this news
Sign up/Log in